行情

AVEO

AVEO

AVEO制药
NASDAQ

实时行情|Nasdaq Last Sale

0.9578
-0.0322
-3.25%
盘后: 0.9850 +0.0272 +2.84% 17:22 09/19 EDT
开盘
1.000
昨收
0.9900
最高
1.010
最低
0.9501
成交量
95.19万
成交额
--
52周最高
3.590
52周最低
0.4906
市值
1.54亿
市盈率(TTM)
-38.7773
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AVEO 新闻

  • AVEO Oncology: Market Approves FOTIVDA's Updated OS HR Ratio
  • Seeking Alpha - Article.6天前
  • Renal Cell Carcinoma Space in Focus: Some Key Developments
  • Zacks.6天前
  • AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?
  • Zacks.6天前
  • 24 Healthcare Stocks Moving In Friday's Pre-Market Session
  • Benzinga.6天前

更多

所属板块

生物技术和医学研究
+0.06%
制药与医学研究
+0.42%

热门股票

名称
价格
涨跌幅

AVEO 简况

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
展开

Webull提供AVEO Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。